Home - Products - Others - Other Targets - Experimental Autoimmune Encephalomyelitis Complementary Peptide

Experimental Autoimmune Encephalomyelitis Complementary Peptide

CAS No. ———

Experimental Autoimmune Encephalomyelitis Complementary Peptide( ——— )

Catalog No. M41943 CAS No. ———

Experimental Autoimmune Encephalomyelitis Complementary Peptide

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Experimental Autoimmune Encephalomyelitis Complementary Peptide
  • Note
    Research use only, not for human use.
  • Brief Description
    Experimental Autoimmune Encephalomyelitis Complementary Peptide
  • Description
    Experimental Autoimmune Encephalomyelitis Complementary Peptide
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    ———
  • Formula Weight
    1197.54
  • Molecular Formula
    C59H100N14O12
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Evonine

    Evonine shows insecticidal activity against Mythimna separata, the LC50 value of 23.23 mg /mL.

  • MID-1

    MID-1 is an inhibitor of MG53-IRS-1 (Mitsugumin 53-Insulin Receptor Substrate-1) interaction.?It disrupts molecular association of MG53 with IRS-1 and abolishes MG53-induced IRS-1 ubiquitination and degradation in skeletal muscle, leading to elevated IRS-1 expression level and increased insulin signaling and glucose uptake.

  • Ganolactone A

    Ganolactone is a triterpenoid compound. Ganolactone has a weak inhibitory effect on EBV early antigen.